Here are 1-2 brief analogies to describe Beta Bionics (BBNX):

• It's like the Tesla for insulin delivery, offering an autonomous, AI-driven system that simplifies managing diabetes.

• Think of it as the Apple of diabetes management devices, making complex insulin delivery intuitive and vastly easier for users.

• iLet Bionic Pancreas: An insulin delivery device that uses adaptive closed-loop algorithms to autonomously determine and deliver insulin doses, simplifying diabetes management by removing the need for carbohydrate counting or manual adjustments.

Beta Bionics (BBNX) sells its product, the iLet Bionic Pancreas, primarily to individuals. The company's major customer categories are:

1. People with Type 1 Diabetes (T1D) currently using Multiple Daily Injections (MDI): A significant portion of the iLet's adoption (approximately 67%) has come from individuals who previously managed their diabetes with MDI, indicating a strong appeal for a simpler, yet more effective treatment option.
2. People with Type 1 Diabetes (T1D) currently using existing insulin pumps or hybrid closed-loop systems: While a smaller percentage of initial adopters, the iLet aims to provide improved glycemic control and a simplified experience compared to more complex existing automated insulin delivery (AID) systems, attracting users seeking an easier way to manage their condition.
3. Children and Adolescents (aged six and older) with Type 1 Diabetes (T1D): The iLet is cleared for patients six and older, and its simplified operation, requiring only body weight for initialization and no carbohydrate counting, is particularly beneficial for younger patients and their caregivers, making diabetes management less burdensome.

Sean Saint, President, CEO & Board Member

Sean Saint is an engineer, entrepreneur, diabetes technologist, and a person with type 1 diabetes. He founded Companion Medical, where he oversaw the development and launch of the InPen system, the first FDA-cleared smart pen, which was subsequently acquired by Medtronic in 2020. Prior to founding Companion Medical, he was an early employee at Dexcom and Tandem Diabetes Care, and also co-founded Alure Medical (now Refine Medical). He assumed the role of CEO at Beta Bionics in August 2022.

Stephen Feider, Chief Financial Officer

Stephen Feider is responsible for the finance, investor relations, human resources, customer service, and IT organizations at Beta Bionics. His experience in the diabetes medical device industry began as Vice President of Finance at Companion Medical, which Medtronic later acquired in 2020. Following the acquisition, he continued his career at Medtronic Diabetes as Finance Director. Earlier in his career, he worked as a CPA at PwC and as Corporate Controller at Marathon Health. He holds both Bachelor's and Master's degrees in Accountancy from Butler University.

Steven Russell, MD, PhD, Chief Medical Officer

Mike Mensinger, Chief Product Officer

Mark Hopman, R.Ph, MBA, Chief Commercial Officer

Key Risks to Beta Bionics (BBNX)

1. Intense Competition and Difficulty in Gaining Market Share: Beta Bionics faces significant challenges in penetrating a market dominated by established players such as Medtronic, Tandem Diabetes Care, Inc., and Insulet Corporation, which collectively hold approximately 96% of the market share for insulin pumps and hybrid closed-loop systems.
2. Heavy Reliance on the Commercial Success and Adoption of a Single Product: The company's business is currently centered on the iLet Bionic Pancreas. The failure of the iLet to achieve widespread adoption or to maintain its market differentiation could severely impact Beta Bionics' financial performance and viability.
3. Challenges in Broad Market Adoption and Payer Reimbursement: Despite the iLet's simplified approach, Beta Bionics must overcome the historical low adoption rates of advanced insulin delivery systems among people with type 1 diabetes and secure favorable reimbursement policies from payers to achieve significant commercial success.

The addressable market for Beta Bionics' main product, the iLet Bionic Pancreas, is approximately 1.8 million people with Type 1 Diabetes (T1D) in the United States.

Beta Bionics (NASDAQ: BBNX) anticipates several key drivers for its future revenue growth over the next 2-3 years, stemming from its innovative iLet Bionic Pancreas system and strategic commercial initiatives.

The expected drivers include:

1. Increasing User Adoption and Expanding Installed Base: Beta Bionics has demonstrated strong traction with its iLet system, evidenced by a 54% year-over-year revenue growth in 2025, reaching $100.3 million, and an installed user base that more than doubled to over 35,000 by the end of 2025. New patient starts continue to grow, with a significant portion (approximately 69%) coming from individuals previously using multiple daily insulin injections (MDI), indicating strong resonance with this underserved market segment.
2. Expansion of Sales Force and Commercial Footprint: To further penetrate the market, Beta Bionics plans to expand its field sales team by at least 20 new territories in 2026, building upon its existing 63 territories. This expansion is strategically aimed at achieving broader U.S. coverage across high-prescribing primary care physicians and endocrinology specialists, thereby increasing access to the iLet system.
3. Growth through Pharmacy Channel Reimbursement: A significant contributor to revenue growth is the rapid expansion of sales through the Pharmacy Benefit Plan (PBP) channel. PBP channel net sales saw a remarkable 287% increase in 2025. The company projects that 36% to 38% of new patient starts in 2026 will be reimbursed via the pharmacy channel, which also contributes to higher-margin revenue.
4. Product Innovation with Mint Patch Pump and Bihormonal System: Beta Bionics is investing in its product pipeline to introduce next-generation solutions. The company is advancing the development of its Mint patch pump, targeting an unconstrained commercial launch by 2027. Additionally, a Phase 2a feasibility trial for a bihormonal system, designed to deliver both insulin and glucagon for more comprehensive glucose management, has been completed. These innovations are expected to broaden the iLet's appeal by offering diverse form factors and enhanced capabilities.
5. Entry into the Type 2 Diabetes Market: While initially focused on Type 1 diabetes, Beta Bionics has observed rising adoption of the iLet among people with Type 2 diabetes (T2D), with this group accounting for approximately 25% to 30% of new patient starts in Q4 2025. Expanding the iLet's reach into the significantly larger T2D population represents a substantial long-term growth opportunity.

Share Issuance

• Beta Bionics completed its initial public offering (IPO) on January 31, 2025, selling 13,800,000 shares of common stock at $17.00 per share.
• In conjunction with the IPO, Beta Bionics sold an additional 1,000,000 shares of common stock to an existing investor in a concurrent private placement at $17.00 per share.
• The aggregate gross proceeds to Beta Bionics from the IPO and the concurrent private placement totaled approximately $229.1 million.

Inbound Investments

• An existing investor made an inbound investment of $17.0 million by purchasing 1,000,000 shares of common stock in a concurrent private placement at the IPO price.
• The company received significant capital from its initial public offering, which closed on January 31, 2025.

Capital Expenditures

• Beta Bionics invested $1.9 million in capital expenditures during the fourth quarter of 2025.
• For the full year 2025, capital expenditures amounted to $5.3 million.
• The company expects operating expenses and capital expenditures to increase as a percentage of revenue in 2026, reflecting ongoing investments.